Cornerstone Wealth Management LLC Buys 1,183 Shares of Novo Nordisk A/S (NYSE:NVO)

Cornerstone Wealth Management LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 26.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,589 shares of the company’s stock after acquiring an additional 1,183 shares during the quarter. Cornerstone Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $481,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the third quarter valued at approximately $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $42,000. Albion Financial Group UT lifted its holdings in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares during the last quarter. Finally, Carolina Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $48,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the subject of several recent research reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $87.94 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The firm has a market cap of $394.65 billion, a P/E ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. The business’s 50 day moving average price is $95.35 and its 200-day moving average price is $115.17.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.